CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic myeloid leukemia.
  
  LEARNING OBJECTIVES

  • Evaluate factors, including age, comorbidities, personal preferences and side-effect profile, that contribute to the selection and sequencing of therapies for chronic-phase (CP) CML, and counsel patients regarding personalized treatment recommendations.
  • Assess pharmacologic similarities and differences among tyrosine kinase inhibitors available for the treatment of CML, and identify which agent is optimal for patients at each stage of the disease course.
  • Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for CML, and appreciate the current role of these agents for patients with relapsed/refractory disease.
  • Consider the biological rationale for and available research findings with STAMP inhibitors as initial treatment for newly diagnosed CP-CML, and recognize the current role of this novel therapeutic strategy.
  • Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with agents commonly employed in the care of patients with CML to support quality of life and continuation of treatment.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.25 (audio) and 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHCML24/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASHCML24/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHCML24/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASHCML24.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Professor Andreas Hochhaus
  Hematology/Oncology
  Jena University Hospital
  Comprehensive Cancer Center Central Germany, Campus Jena
  Jena, Germany
  
  Consulting Agreements: Novartis; Contracted Research: Enliven Therapeutics, Incyte Corporation, Novartis, Pfizer Inc, Terns Pharmaceuticals.
  
  B Douglas Smith, MD
  Professor, Oncology — Division of Hematologic Malignancies
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  Baltimore, Maryland
  
  Consulting Agreements: Bristol Myers Squibb, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC.
  
  MODERATOR
  Michael J Mauro, MD
  Director, Chronic Myeloid Leukemia Program
  Attending Physician, Leukemia Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committees and Consulting Agreements: Bristol Myers Squibb, Enliven Therapeutics, Novartis, Takeda Pharmaceuticals USA Inc, Terns Pharmaceuticals; Contracted Research: Enliven Therapeutics, Novartis, Terns Pharmaceuticals, Sun Pharma Advanced Research Company (SPARC), Sun Pharmaceutical Industries Ltd.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Novartis.
  
  Release date: January 2025
  Expiration date: January 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.